GAD1 and type 1 diabetes mellitus: Anti-GAD and anti-islet antibodies demonstrated significantly higher positivity rates in the T1DM group (69.0% and 64.1%, respectively) compared to T2DM (7.4% and 3.8%; p < 0.0001).